A comprehensive guide to the critical clauses, financial instruments, and strategic considerations for biotech founders using Simple Agreements for Future Equity (SAFE). Given the high capital intensity and long R&D timelines of life sciences, these elements ensure alignment between founders and early investors.
Get targeted exposure with custom position pinning and highlighted placement.
A ceiling on the price at which the SAFE converts into equity during a priced round. In biotech, this protects early risk-takers by ensuring they receive a larger equity stake if the company's value skyrockets after a successful preclinical milestone.
A percentage reduction offered to early investors relative to the price paid by Series A investors. This rewards pre-seed backers for taking on extreme early-stage technical risk before proof-of-concept data is fully established.
A modern SAFE variation that defines ownership based on the company's capitalization immediately after the SAFE converts. This provides biotech founders and investors with more clarity on dilution before the first major venture round.
Contractual rights allowing investors to maintain their percentage ownership in subsequent funding rounds. This is vital for biotech investors who wish to continue funding the company through expensive Phase I and II clinical trials.
Structuring the SAFE investment to release funds upon achieving specific technical goals, such as Lead Optimization or IND filing. This mitigates investor risk while providing founders with the capital needed to reach the next valuation inflection point.
A provision ensuring that if the startup issues future SAFEs with better terms, the original investor receives those same terms. This is common when biotech firms raise multiple small checks from different angel investors over several months.
Terms defining what happens if the biotech company is acquired before a priced round occurs. It specifies whether the SAFE holder receives a cash payout or converts their investment into common stock to participate in the exit.
The specific event, typically a qualified financing round of a minimum dollar amount, that triggers the conversion of the SAFE into preferred shares. This prevents premature conversion from small bridge rounds or internal seed extensions.
A prerequisite document ensuring all founders and employees have transferred intellectual property rights to the company. Investors will rarely sign a SAFE if the core biotech patents are not legally owned by the entity receiving the funds.
A non-voting right for significant SAFE investors to attend board meetings. In highly technical biotech ventures, this allows experienced life-science investors to provide strategic guidance on regulatory pathways without formal fiduciary control.
The minimum amount of capital that must be raised in a priced round to trigger the automatic conversion of the SAFE. This ensures the company has enough runway to actually operate before the complexity of a full equity table is introduced.
A requirement that founder shares vest over time (typically 4 years) to ensure long-term commitment. Since biotech R&D takes years, investors use this to prevent founders from leaving with a large equity stake early on.
Supplemental documents used to negotiate specific terms not found in the standard YC SAFE template. These are often used in biotech to handle complex issues like university licensing obligations or specific reporting requirements.
Digital tools used to track the potential dilution caused by SAFEs, options, and common stock. Accurate tracking is essential for biotech startups to present a clean equity structure to Tier 1 VC firms during Series A.
A clause determining the order of payment if the company shuts down. SAFE holders typically have priority over common shareholders but are secondary to secured creditors, which is critical given the high failure rate of drug discovery.
The process of timing the SAFE's conversion or subsequent rounds with FDA or EMA milestones. Aligning funding cycles with data readouts maximizes the valuation cap for the founders during the conversion event.
Mechanisms that protect investors from ownership reduction during subsequent 'down rounds'. While less common in basic SAFEs, specialized biotech versions may include protections to keep strategic partners incentivized.
Explicitly stating that SAFE holders have no voting rights until the instrument converts to equity. This allows biotech founders to make rapid technical and strategic pivots without needing approval from a fragmented group of angel investors.
Specific requirements that must be met before the funds are transferred, such as the completion of a patent search or the signing of a Material Transfer Agreement (MTA) with a research university.
Terms specifying whether legal fees for drafting the SAFE and accompanying documents are paid by the company or the investors. In pre-seed biotech, these are often capped to preserve precious early-stage runway.